Evidence map›Paper›PMID 34370182›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2022

In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

M D Matossian, T Chang, M K Wright, H E Burks, S Elliott, R A Sabol, H Wathieu, G O Windsor, M S Alzoubi, C T King and 23 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 9 institutions in 1 country.

M D MatossianDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
T ChangDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
M K WrightDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
H E BurksDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
S ElliottDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
R A SabolTulane Center for Stem Cell Research and Regenerative Medicine, New Orleans, LA, USA.
H WathieuDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
G O WindsorDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
M S AlzoubiDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
C T KingDepartment of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
J B BursavichDepartment of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
A M HamDepartment of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
J J SavoieDepartment of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
K NguyenDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
M BaddooCancer Genetics Program, Tulane University School of Medicine, New Orleans, LA, USA.
E FlemingtonCancer Genetics Program, Tulane University School of Medicine, New Orleans, LA, USA.
O SirenkoMolecular Devices LLC, San Jose, CA, USA.
E F CromwellProtein Fluidics Inc, Burlingame, CA, USA.
K L HebertDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
F LauDepartment of Surgery, Section of Plastic & Reconstructive Surgery, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
R IzadpanahTulane Cancer Center, New Orleans, LA, USA.
H BrownInnogenomics Technologies LLC, New Orleans, LA, USA.
S SinhaInnogenomics Technologies LLC, New Orleans, LA, USA.
J ZabaletaDepartment of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
A I RikerCancer Service Line, Anne Arundel Medical Center, Luminis Health, DeCesaris Cancer Institute, Annapolis, MD, USA.
K MorozLouisiana Cancer Research Center, Biospecimen Core, New Orleans, LA, USA.
L MieleStanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
A H ZeaLouisiana Cancer Research Center, Biospecimen Core, New Orleans, LA, USA.
A OchoaStanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
B A BunnellDepartment of Microbiology, Immunology, and Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA.
B M Collins-BurowDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
E C MartinDepartment of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
M E BurowDepartment of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA. mburow@tulane.edu.ORCID http://orcid.org/0000-0002-0642-6630
Tulane University · USLouisiana State University · USLouisiana State University Health Sciences Center New Orleans · USInnoGenomics (United States) · USAdvanced Fluidics (United States) · USAnalog Devices (United States) · USAnne Arundel Medical Center · USLouisiana Cancer Research Center · USUniversity of North Texas · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Leigh Lamonica · 2012 to 2026
$69.1M
Kinase mediated suppression of metastasis in breast cancerR01CA174785 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI COLLINS-BUROW, BRIDGETTE MICHELLE · 2016 to 2020
$1.8M
Maximizing Access to Research Careers at Louisiana State UniversityT34GM136452 · NIGMS · LOUISIANA STATE UNIV A&M COL BATON ROUGE · PI VICENTE, MARIA DA GRACA HENRIQUES · 2020 to 2024
$1.6M
MEK5-Erk5 in breast cancer resistanceR01CA125806 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI BUROW, MATTHEW E. · 2010 to 2014
$1.5M
Interdisciplinary Predoctoral Training in BioinnovationT32EB027632 · NIBIB · TULANE UNIVERSITY OF LOUISIANA · PI GAVER, DONALD P. · 2019 to 2023
$813k
Novel small molecule inhibitors of MEK5_ERK5 for the treatment of breast cancerR15CA176496 · NCI · DUQUESNE UNIVERSITY · PI CAVANAUGH, JANE E · 2014 to 2014
$394k
NCI NIH HHS R01 CA125806NCI NIH HHS R01 CA174785NCI NIH HHS R15 CA176496NIBIB NIH HHS T32 EB027632NIGMS NIH HHS T34 GM136452NIGMS NIH HHS U54 GM104940NIH HHS 1R15CA176496-01A1NIH HHS R01-CA125806-04NIH HHS R01-CA174785-A1
6 · The paper itself

Abstract

Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to evaluate tumor biology of rare subtypes. Here, we provide an in-depth comprehensive characterization of a new PDX model for MBC, TU-BcX-4IC. TU-BcX-4IC is a clinically aggressive tumor exhibiting rapid growth in vivo, spontaneous metastases, and elevated levels of cell-free DNA and circulating tumor cell DNA. Relative chemosensitivity of primary cells derived from TU-BcX-4IC was performed using the National Cancer Institute (NCI) oncology drug set, crystal violet staining, and cytotoxic live/dead immunofluorescence stains in adherent and organoid culture conditions. We employed novel spheroid/organoid incubation methods (Pu·MA system) to demonstrate that TU-BcX-4IC is resistant to paclitaxel. An innovative physiologically relevant system using human adipose tissue was used to evaluate presence of cancer stem cell-like populations ex vivo. Tissue decellularization, cryogenic-scanning electron microscopy imaging and rheometry revealed consistent matrix architecture and stiffness were consistent despite serial transplantation. Matrix-associated gene pathways were essentially unchanged with serial passages, as determined by qPCR and RNA sequencing, suggesting utility of decellularized PDXs for in vitro screens. We determined type V collagen to be present throughout all serial passage of TU-BcX-4IC tumor, suggesting it is required for tumor maintenance and is a potential viable target for MBC. In this study we introduce an innovative and translational model system to study cell-matrix interactions in rare cancer types using higher passage PDX tissue.

Indexed as

Models, BiologicalAnimalsAntineoplastic AgentsDisease Models, AnimalHeterograftsHumansTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysAntineoplastic AgentsCollagenExtracellular matrixMetaplastic breast carcinomaPatient-derived xenograftTriple negative breast cancer

Identifiers

PMID34370182
PMCPMC8732292
OpenAlexW3192067220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.